Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow FIBROGEN INC

Get SEC filing alerts via email and in your feed for FIBROGEN INC

FGEN

FIBROGEN INC

About FIBROGEN INC

FibroGen, Inc. is a biopharmaceutical company focused on developing therapies for anemia and cancer. Its key products include roxadustat, an oral treatment for anemia in chronic kidney disease and myelodysplastic syndromes, and FG-3246, an antibody-drug conjugate targeting cancer. The company collaborates globally, with a core business model centered on drug development, licensing, and strategic partnerships in markets like China, Europe, and Japan.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from FIBROGEN INC

1
1
FIBROGEN INC Kyntra Bio Reports 36% Revenue Growth to $3.738 Million in Q1 2026

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
FIBROGEN INC Kyntra Bio Reports 78% Revenue Decline to $6.4 Million for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
FIBROGEN INC FibroGen Reports 99% Revenue Decline and Significant Operational Changes in Latest 10-Q

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
FIBROGEN INC FibroGen Reports 35% Revenue Decline in Q2 2025, Plans Sale of Subsidiary to AstraZeneca

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
FIBROGEN INC FibroGen Reports 89% Revenue Decline, Plans Phase 2 Study Amid Liquidity Concerns

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
FIBROGEN INC Fibrogen Reports 37% Revenue Decline to $29.6 Million for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
FIBROGEN INC FibroGen Reports 15% Revenue Growth, Improved Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments